subhead]Adjuvant chemotherapy after treatment with neoadjuvant folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) was not associated with improved overall survival (OS) in patients with resected pancreatic cancer, according to results from an international, multicenter, retrospective cohort study. [/subhead]
However, adjuvant chemotherapy after neoadjuvant FOLFIRINOX and resection of pancreatic cancer was associated with improved survival in a subset of patients with pathology-proven node-positive disease.Read more . . .